Sotrovimab Lowers the Risk of COVID-19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates

Article Infectious Diseases

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial

Mohammad Bosaeed et al.

Summary: Favipiravir treatment does not reduce the time to viral clearance in mild COVID-19 cases.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Article Infectious Diseases

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Wesley H. Self et al.

Summary: This study assessed the efficacy and safety of two neutralising monoclonal antibody therapies for adults hospitalised with COVID-19. The results showed that neither of the therapies showed significant improvement in clinical outcomes among COVID-19 patients.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

Emi Takashita et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-19

Richard Whitley

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Anil Gupta et al.

Summary: The study showed that sotrovimab treatment significantly reduced the risk of all-cause hospitalization or death in nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression. Sotrovimab also decreased the risk of emergency department visits, hospitalization, or death, as well as the progression to severe or critical respiratory COVID-19. Adverse events were similar between the treatment and placebo groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Letter Medicine, General & Internal

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Emi Takashita et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Immunology

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19)

Adarsh Bhimraj et al.

Summary: This article introduces the guidelines developed by the Infectious Diseases Society of America for the treatment and management of COVID-19. The guideline panel regularly reviews the evidence and uses the GRADE approach to assess the certainty of evidence and make recommendations. The panel has made 32 recommendations for different groups/populations, including prophylaxis, ambulatory patients with mild-to-moderate disease, and hospitalized patients. These are living guidelines and the most recent recommendations can be found on the specified website.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Zarir F. Udwadia et al.

Summary: The study aimed to assess the efficacy and safety of favipiravir in adults with mild-to-moderate COVID-19. Results showed a significant improvement in time to clinical cure with favipiravir, although there was no statistically significant difference in viral shedding cessation time.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta et al.

Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

Jean-Selim Driouich et al.

Summary: Despite limited pre-clinical evidence, repurposed drugs such as favipiravir are being extensively evaluated in clinical trials to combat the lack of antiviral options against SARS-CoV-2. Favipiravir shows strong antiviral efficacy in a Syrian hamster model, with high doses reducing viral infectivity while inducing mutations in viral genomes. However, toxicity concerns are noted at the highest tested dose, requiring further pharmacokinetic and tolerance studies before potential human use.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Multidisciplinary Sciences

The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Soheil Hassanipour et al.

Summary: The meta-analysis of Favipiravir in the treatment of COVID-19 showed significant clinical improvement in the Favipiravir group compared to the control group after seven days of hospitalization. However, there was no significant difference in viral clearance and oxygen therapy requirement between the two groups. The mortality rate was approximately 30% lower in the Favipiravir group, but this finding was not statistically significant.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Multidisciplinary Sciences